ATRA

7.25

5.69% 0.39

Handel nachbörslich: 7.24 -0.010 -0.14%

Atara Biotherapeutics Inc (ATRA)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ATRA? Forum Prognose

Schlusskurs vom Vortag:

$6.86

Offen:

$6.97

24-Stunden-Volumen:

28,314

Relative Volume:

0.14

Marktkapitalisierung:

$42.48M

Einnahmen:

$100.44M

Nettoeinkommen (Verlust:

$-133.16M

KGV:

-0.2814

EPS:

-25.76

Netto-Cashflow:

$-94.85M

1W Leistung:

+5.07%

1M Leistung:

-15.60%

6M Leistung:

-25.41%

1J Leistung:

-53.97%

1-Tages-Spanne:

$6.6701

$7.25

1-Wochen-Bereich:

$5.94

$7.25

52-Wochen-Spanne:

$5.40

$20.81

Atara Biotherapeutics Inc Stock (ATRA) Company Profile

Firmenname

Atara Biotherapeutics Inc

Sektor

Healthcare (1171)

Branche

Biotechnology (675)

Telefon

805-623-4211

Adresse

1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA

Mitarbeiter

153

Twitter

@Atarabio

Nächster Verdiensttermin

2024-11-18

Neueste SEC-Einreichungen

ATRA's Discussions on Twitter

Vergleichen Sie ATRA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ATRA Atara Biotherapeutics Inc	7.25	42.48M	100.44M	-133.16M	-94.85M	-25.76
VRTX Vertex Pharmaceuticals Inc	504.77	129.62B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	666.87	72.91B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	604.96	36.76B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.76	31.30B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	259.19	27.86B	3.32B	-860.46M	-1.04B	-8.32

Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-09	Herabstufung	Evercore ISI	Outperform → In-line
2023-11-09	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-11-09	Herabstufung	Mizuho	Buy → Neutral
2022-07-20	Herabstufung	Citigroup	Neutral → Sell
2022-07-13	Herabstufung	JP Morgan	Overweight → Neutral
2022-07-13	Herabstufung	Stifel	Buy → Hold
2022-05-10	Herabstufung	Citigroup	Buy → Neutral
2021-05-13	Hochstufung	JP Morgan	Neutral → Overweight
2020-12-09	Herabstufung	Citigroup	Buy → Neutral
2020-12-08	Bestätigt	H.C. Wainwright	Buy
2020-11-10	Bestätigt	H.C. Wainwright	Buy
2020-06-30	Eingeleitet	Evercore ISI	Outperform
2020-06-15	Eingeleitet	H.C. Wainwright	Buy
2020-04-23	Hochstufung	Citigroup	Neutral → Buy
2019-11-08	Herabstufung	JP Morgan	Overweight → Neutral
2019-09-27	Herabstufung	Goldman	Neutral → Sell
2019-09-16	Herabstufung	Jefferies	Buy → Hold
2019-06-04	Hochstufung	Citigroup	Sell → Neutral
2019-05-30	Eingeleitet	ROTH Capital	Buy
2019-05-23	Eingeleitet	Stifel	Buy
2019-01-23	Eingeleitet	Mizuho	Buy
2018-04-10	Eingeleitet	JP Morgan	Overweight
2018-03-16	Eingeleitet	Guggenheim	Neutral
2018-03-05	Bestätigt	Jefferies	Buy
2018-02-28	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2018-02-15	Herabstufung	Citigroup	Neutral → Sell
2018-01-03	Hochstufung	Citigroup	Sell → Neutral
2017-10-06	Fortgesetzt	Goldman	Neutral

Alle ansehen

Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten

Mar 13, 2025

Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Mar 13, 2025

Mar 12, 2025

Atara Biotherapeutics (NASDAQ:ATRA) Given Buy Rating at Canaccord Genuity Group - Defense World

Mar 12, 2025

Mar 11, 2025

Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement - TipRanks

Mar 11, 2025

Mar 10, 2025

Atara Biotherapeutics: Q4 Earnings Snapshot - The Bakersfield Californian

Mar 10, 2025

Mar 09, 2025

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 09, 2025

Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes - TipRanks

Mar 09, 2025

Mar 07, 2025

Atara Biotherapeutics Reports 2024 Financial Results - TipRanks

Mar 07, 2025

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress - BioSpace

Mar 07, 2025

Lacklustre Performance Is Driving Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) 27% Price Drop - Simply Wall St

Mar 07, 2025

Mar 06, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock By Investing.com - Investing.com Australia

Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock By Investing.com - Investing.com South Africa

Mar 06, 2025

Atara biotherapeutics EVP and CFO Eric Hyllengren sells $8,473 in stock - Investing.com Australia

Mar 06, 2025

Mar 05, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is i - GuruFocus.com

Mar 05, 2025

Atara biotherapeutics EVP sells $7,409 in common stock - Investing.com India

Mar 05, 2025

Nguyen AnhCo, CEO of Atara Biotherapeutics, sells $23,307 in stock - Investing.com India

Mar 05, 2025

Mar 04, 2025

Trading (ATRA) With Integrated Risk Controls - Stock Traders Daily

Mar 04, 2025

Mar 03, 2025

Atara Biotherapeutics Inc To Cut 50% Of Workforce -March 03, 2025 at 05:26 pm EST - Marketscreener.com

Mar 03, 2025

Feb 27, 2025

Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet - MSN

Feb 27, 2025

Feb 26, 2025

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Average Rating of “Moderate Buy” from Analysts - Defense World

Feb 26, 2025

Feb 21, 2025

(ATRA) Investment Analysis - Stock Traders Daily

Feb 21, 2025

Feb 14, 2025

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws - Finansavisen

Feb 14, 2025

Feb 12, 2025

Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online

Feb 12, 2025

Feb 11, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Longview News-Journal

Feb 11, 2025

How the (ATRA) price action is used to our Advantage - Stock Traders Daily

Feb 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation - Markets Insider

Feb 11, 2025

Feb 10, 2025